Insider Selling: Enliven Therapeutics, Inc. (NASDAQ:ELVN) Insider Sells $257,625.00 in Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN) insider Joseph P. Lyssikatos sold 12,500 shares of the business’s stock in a transaction on Wednesday, March 19th. The stock was sold at an average price of $20.61, for a total value of $257,625.00. Following the completion of the transaction, the insider now owns 1,002,688 shares of the company’s stock, valued at $20,665,399.68. This represents a 1.23 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Enliven Therapeutics Stock Performance

Enliven Therapeutics stock opened at $21.08 on Monday. Enliven Therapeutics, Inc. has a one year low of $15.96 and a one year high of $30.03. The stock has a fifty day moving average of $21.31 and a 200 day moving average of $23.78. The stock has a market cap of $1.03 billion, a PE ratio of -11.09 and a beta of 1.04.

Enliven Therapeutics (NASDAQ:ELVN) last released its quarterly earnings results on Thursday, March 13th. The company reported ($0.46) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.53) by $0.07. The firm had revenue of $0.03 million for the quarter. As a group, sell-side analysts predict that Enliven Therapeutics, Inc. will post -1.95 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on ELVN shares. BTIG Research started coverage on Enliven Therapeutics in a report on Friday, December 13th. They issued a “buy” rating and a $42.00 price objective for the company. HC Wainwright lifted their price target on shares of Enliven Therapeutics from $37.00 to $39.00 and gave the stock a “buy” rating in a research note on Friday. Four research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of $38.75.

Hedge Funds Weigh In On Enliven Therapeutics

Hedge funds have recently made changes to their positions in the business. Quest Partners LLC raised its stake in Enliven Therapeutics by 1,226.4% during the 3rd quarter. Quest Partners LLC now owns 21,117 shares of the company’s stock valued at $539,000 after purchasing an additional 19,525 shares during the period. Charles Schwab Investment Management Inc. grew its holdings in Enliven Therapeutics by 10.4% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 255,277 shares of the company’s stock valued at $6,520,000 after buying an additional 24,043 shares in the last quarter. The Manufacturers Life Insurance Company raised its position in shares of Enliven Therapeutics by 25.6% during the third quarter. The Manufacturers Life Insurance Company now owns 17,282 shares of the company’s stock valued at $441,000 after buying an additional 3,518 shares during the last quarter. FMR LLC lifted its holdings in shares of Enliven Therapeutics by 10.6% in the third quarter. FMR LLC now owns 6,296,179 shares of the company’s stock worth $160,804,000 after buying an additional 601,611 shares in the last quarter. Finally, Ally Bridge Group NY LLC bought a new position in shares of Enliven Therapeutics during the third quarter worth $5,998,000. Institutional investors own 95.08% of the company’s stock.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.